Segmed – Weekly Recap

Segmed is a healthcare data platform specializing in de-identified clinical and medical imaging data, and this weekly recap highlights several developments that reinforce its focus on regulatory-grade, privacy-safe real-world data for research and AI applications.

The company announced that it has obtained an independent HIPAA Expert Determination confirming that its de-identification processes for structured clinical data, imaging pixels, and radiology text meet the U.S. HIPAA standard for de-identified data. The review, led by statistical privacy experts, concluded there is no reasonable basis to believe individuals could be re-identified from Segmed’s datasets. This validation covers some of the most complex healthcare data types and is supported by a de-identification framework that combines automated algorithms with human quality review to remove direct identifiers and mitigate indirect identifiers while preserving research utility. Segmed also underscored that it maintains SOC 2 Type 2 and ISO 27001 certifications, signaling sustained investment in security, governance, and enterprise-grade controls.

In parallel, Segmed highlighted the increasing importance of real-world imaging data as a source of real-world evidence in regulatory decision-making, particularly for the U.S. FDA. The company emphasized that “regulatory-grade” imaging data requires more than scale, pointing to data provenance, harmonization, audit readiness, standardized acquisition, clinical context, validated analytics, and transparent data pipelines as key elements. Segmed positions its platform as providing de-identified, regulatory-grade imaging datasets with full provenance and multilayer quality controls, designed to support use cases such as surrogate endpoints, post-market surveillance, AI validation, and FDA submissions.

Further reinforcing its position in the healthcare data and AI ecosystem, Segmed announced its role as co-organizer of a JPM2026 side event in San Francisco, hosted by Cromodata, focused on how artificial intelligence and real-world evidence are transforming healthcare. CEO David Gascoigne is slated to join a panel on secure, anonymized data and trusted data ecosystems, highlighting the company’s ongoing thought leadership and engagement with industry stakeholders.

Taken together, these developments strengthen Segmed’s profile as a compliant, security-focused provider of real-world clinical and imaging data, and support its efforts to serve biopharma, medtech, and AI developers that require high-quality, privacy-safe, and regulatory-ready datasets. The week’s updates point to a company concentrating on regulatory alignment, data quality, and ecosystem engagement as key pillars of its long-term growth strategy.